GlassScriptPhysician profile
Indulekha N Gopal
NPI 1700831088
$2,774.34
in general payments reported to CMS, 2019-2025
24 companies · $97.89 in 2025
The $97.89 reported for 2025 was less than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,348 · 2020: $313 · 2021: $141 · 2022: $250 · 2023: $250 · 2024: $375 · 2025: $97.89.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $723.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $722.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $374.99 | 2021-2024 | Arexvy |
| Amgen INC. | $249.98 | 2023-2024 | Otezla, Repatha |
| Cipla USA INC. | $222.96 | 2019 | |
| Merck Sharp & Dohme LLC | $184.11 | 2019-2020 | |
| Tetraphase Pharmaceuticals, INC. | $156.15 | 2019-2020 | |
| Gilead Sciences, INC. | $150.04 | 2019 | |
| Cumberland Pharmaceuticals, INC. | $140.83 | 2019-2020 | |
| Pfizer INC. | $124.99 | 2019 | |
| Novo Nordisk INC | $124.99 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $124.99 | 2024 | Tezspire |
| Janssen Pharmaceuticals, INC | $124.99 | 2019 | |
| Lilly USA, LLC | $124.99 | 2023 | Mounjaro |
| Mylan Specialty L.P. | $108.53 | 2019-2020 | |
| Shionogi INC | $97.89 | 2025 | Fetroja |
| Melinta Therapeutics, LLC | $96.91 | 2019-2020 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $91.03 | 2019-2020 | |
| Vyera Pharmaceuticals, LLC | $65.90 | 2019 | |
| Insmed, INC. | $51.48 | 2019-2020 | |
| Nabriva Therapeutics, Plc | $47.35 | 2020 | |
| Paratek Pharmaceuticals, INC. | $38.99 | 2019 | |
| Viiv Healthcare Company | $29.93 | 2019 | |
| Abbvie INC. | $16.07 | 2021 | |
| Astellas Pharma US INC | $13.77 | 2019 | |
| Mylan Institutional INC. | $12.48 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Indulekha Gopal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.